Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737712 | 1.00 | LMNA (0.53) | LMNAKMT2APOLBALDH1A1MMP12 | |
| SCHEMBL16509806 | 0.92 | LMNA (0.54) | LMNAKMT2APOLBALDH1A1MMP12 | |
| SCHEMBL13694945 | 0.92 | LMNA (0.54) | LMNAKMT2APOLBALDH1A1MMP12 | |
| SCHEMBL17339928 | 0.88 | TNF (0.45) | LMNAKMT2ATNFTSHRCASP3 | |
| SCHEMBL1737629 | 0.86 | LMNA (0.55) | LMNAKMT2APOLBALDH1A1MMP12 | |
| SCHEMBL16509808 | 0.83 | LMNA (0.45) | LMNAKMT2APOLBALDH1A1KDM4E | |
| SCHEMBL13694940 | 0.83 | LMNA (0.45) | LMNAKMT2APOLBALDH1A1KDM4E | |
| SCHEMBL10038955 | 0.83 | CASP3 (0.42) | KMT2ATNFCASP3 | |
| SCHEMBL16244990 | 0.82 | LMNA (0.54) | LMNAKMT2APOLBALDH1A1MMP12 | |
| SCHEMBL6044028 | 0.82 | LMNA (0.50) | LMNAKMT2APOLBALDH1A1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446144-B2 | Glycopeptide and uses thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20140212473-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212473-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | LMNA 3351/4885KMT2A 4129/4885POLB 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.